에서 실시간으로 운영 중이에요! 자세히 알아보기

CATALENT, INC.

CTLT

시가총액 US$115억

상장 폐지됨

CTLT은(는) 2024년 12월 17일에 상장 폐지됐어요.

순위로 돌아가기

소개: Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.

직원 수: 16,900

건강관리 제약 - 종합

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 0%

중립 0%

부정적 0%

Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say

All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transaction is expected to be completed in the coming days.

Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say

Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close

Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S's pending acquisition of Catalent, Inc. (Catalent), including expiry of the timing agreement in the US, have been fulfilled. Catalent is a global contract development and manufacturing organisation headquartered in New Jersey (US). The parties are now free to close the transaction, as well as Novo Nordisk's subsequent acquisition of three Catalent manufacturing sites from Novo Holdings A/S.

Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close

Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction

SOMERSET, N.J. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life sciences investment firm, today announced that the companies have fulfilled all regulatory closing conditions for their pending transaction. The companies now expect to close the transaction in the coming days. “Today represents an important step in our t.

Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction

The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings

Bagsværd, Denmark, 6 December 2024 — Today, the European Commission approved Novo Holdings A/S' acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in New Jersey (US), as well as Novo Nordisk's subsequent acquisition of three manufacturing sites from Novo Holdings A/S.

The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings

Catalent and Novo Holdings Receive European Commission Unconditional Approval for Pending Transaction

SOMERSET, N.J. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life sciences investment firm, today announced that the European Commission (EC) has granted unconditional approval for the pending transaction under which Novo Holdings will acquire Catalent. “We are pleased to have received European Commission approval, whic.

Catalent and Novo Holdings Receive European Commission Unconditional Approval for Pending Transaction

Novo Holdings' $16.5 bln Catalent buy wins EU antitrust approval

Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker Catalent after EU regulators said they did not see any competition issues.

Novo Holdings' $16.5 bln Catalent buy wins EU antitrust approval

Zacks Investment Research

Why Is Catalent (CTLT) Up 3.2% Since Last Earnings Report?

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?

Why Is Catalent (CTLT) Up 3.2% Since Last Earnings Report?

EU antitrust regulators set to okay $16.5 bln Novo Holdings, Catalent deal, source says

EU antitrust regulators are set to clear without conditions Novo Holdings' planned $16.5 billion takeover of Catalent , a person with direct knowledge of the matter said on Friday.

EU antitrust regulators set to okay $16.5 bln Novo Holdings, Catalent deal, source says

EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' planned $16.5 billion takeover of Catalent , people familiar with the matter said.

EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal

Zacks Investment Research

JAZZ or CTLT: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Drugs stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT). But which of these two stocks is more attractive to value investors?

JAZZ or CTLT: Which Is the Better Value Stock Right Now?

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.